ifosfamide has been researched along with Central Nervous System Neoplasm in 28 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "High-dose methotrexate is the standard of care for patients with newly diagnosed primary CNS lymphoma." | 9.14 | High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. ( Bamberg, M; Birnbaum, T; Fischer, L; Griesinger, F; Herrlinger, U; Hertenstein, B; Hundsberger, T; Jahnke, K; Kanz, L; Korfel, A; Leithäuser, M; Martus, P; Mergenthaler, HG; Nägele, T; Pietsch, T; Plasswilm, L; Rauch, M; Röth, A; Thiel, E; von Toll, T; Weller, M, 2010) |
| " Our objective was to assess the efficacy, security, and survival rate of postoperative chemotherapy with ifosfamide, carboplatin, and etoposide (ICE) in pediatric patients with anaplastic astrocytomas (AA) and glioblastoma multiforme (GM)." | 9.10 | Preirradiation ifosfamide, carboplatin and etoposide (ICE) for the treatment of high-grade astrocytomas in children. ( Cerecedo-Díaz, F; Delgado-Huerta, S; Hernández-Contreras, I; López-Aguilar, E; Ramón-García, G; Rivera-Márquez, H; Rodríguez-Jiménez, H; Romo-Rubio, HA; Santacruz-Castillo, E; Sepúlveda-Vildósola, AC; Valdés-Sánchez, M; Wanzke-del Angel, V, 2003) |
| "In the present study, we aimed to evaluate the safety and efficacy of DeVIC (dexamethasone, etoposide, ifosfamide and carboplatin) chemotherapy for the treatment of patients with primary central nervous system lymphoma (PCNSL)." | 7.77 | Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy. ( Fujii, M; Ito, M; Momota, H; Motomura, K; Natsume, A; Wakabayashi, T, 2011) |
| "Childhood neuroblastoma is a neural crest-derived tumor that presents most commonly during this period of life." | 5.28 | Combination chemotherapy with ifosfamide and etoposide is effective in the treatment of central nervous system metastasis of childhood neuroblastoma. ( Watts, RG, 1992) |
| "High-dose methotrexate is the standard of care for patients with newly diagnosed primary CNS lymphoma." | 5.14 | High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. ( Bamberg, M; Birnbaum, T; Fischer, L; Griesinger, F; Herrlinger, U; Hertenstein, B; Hundsberger, T; Jahnke, K; Kanz, L; Korfel, A; Leithäuser, M; Martus, P; Mergenthaler, HG; Nägele, T; Pietsch, T; Plasswilm, L; Rauch, M; Röth, A; Thiel, E; von Toll, T; Weller, M, 2010) |
| " Our objective was to assess the efficacy, security, and survival rate of postoperative chemotherapy with ifosfamide, carboplatin, and etoposide (ICE) in pediatric patients with anaplastic astrocytomas (AA) and glioblastoma multiforme (GM)." | 5.10 | Preirradiation ifosfamide, carboplatin and etoposide (ICE) for the treatment of high-grade astrocytomas in children. ( Cerecedo-Díaz, F; Delgado-Huerta, S; Hernández-Contreras, I; López-Aguilar, E; Ramón-García, G; Rivera-Márquez, H; Rodríguez-Jiménez, H; Romo-Rubio, HA; Santacruz-Castillo, E; Sepúlveda-Vildósola, AC; Valdés-Sánchez, M; Wanzke-del Angel, V, 2003) |
| "In the present study, we aimed to evaluate the safety and efficacy of DeVIC (dexamethasone, etoposide, ifosfamide and carboplatin) chemotherapy for the treatment of patients with primary central nervous system lymphoma (PCNSL)." | 3.77 | Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy. ( Fujii, M; Ito, M; Momota, H; Motomura, K; Natsume, A; Wakabayashi, T, 2011) |
| " We conducted a phase 1 trial to evaluate the safety of olaratumab and determine a recommended dose in combination with three different chemotherapy regimens in children." | 3.01 | Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors. ( Bishop, MW; Borinstein, SC; DuBois, SG; Hingorani, P; Krystal, J; Laetsch, TW; Levy, DE; Mascarenhas, L; Mo, G; Muscal, JA; Ogawa, C; Shahir, A; Slotkin, EK; Weigel, BJ; Wright, J, 2021) |
| "Ifosfamide (IFO) is a widely used antitumor agent, requiring activation to isophosphoramide mustard (IPM) for DNA alkylation." | 2.43 | Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention. ( Lokiec, F, 2006) |
| " TOPO dosage was 3." | 1.37 | Topotecan and ifosfamide systemic chemotherapy for CNS involvement of solid tumors. ( Kiewe, P; Korfel, A; Reinwald, M; Thiel, E, 2011) |
| "He was given a diagnosis of Burkitt's lymphoma and was in clinical stage II B." | 1.30 | [Successful treatment with high dose chemotherapy following peripheral blood stem cell transplantation for relapsed Burkitt's lymphoma with central nervous system involvement]. ( Kondo, E; Miura, A; Mizuno, H; Yamao, H; Yuge, M, 1998) |
| "Childhood neuroblastoma is a neural crest-derived tumor that presents most commonly during this period of life." | 1.28 | Combination chemotherapy with ifosfamide and etoposide is effective in the treatment of central nervous system metastasis of childhood neuroblastoma. ( Watts, RG, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.14) | 18.2507 |
| 2000's | 9 (32.14) | 29.6817 |
| 2010's | 15 (53.57) | 24.3611 |
| 2020's | 2 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Ostrowska, B | 1 |
| Domanska-Czyz, K | 1 |
| Romejko-Jarosinska, J | 1 |
| Osowiecki, M | 1 |
| Targonski, L | 1 |
| Poplawska, L | 1 |
| Konecki, R | 1 |
| Kotarska, M | 1 |
| Szymanski, M | 1 |
| Borawska, A | 1 |
| Swierkowska, M | 1 |
| Dabrowska-Iwanicka, A | 1 |
| Druzd-Sitek, A | 1 |
| Paszkiewicz-Kozik, E | 1 |
| Mroz-Zycinska, E | 1 |
| Tajer, J | 1 |
| Wojciechowska-Lampka, E | 1 |
| Osiadacz, W | 1 |
| Rymkiewicz, G | 1 |
| Lapinska, G | 1 |
| Wojewodzka-Mirocha, M | 1 |
| Michalski, W | 1 |
| Walewski, J | 1 |
| Mascarenhas, L | 1 |
| Ogawa, C | 1 |
| Laetsch, TW | 1 |
| Weigel, BJ | 1 |
| Bishop, MW | 1 |
| Krystal, J | 1 |
| Borinstein, SC | 1 |
| Slotkin, EK | 1 |
| Muscal, JA | 1 |
| Hingorani, P | 1 |
| Levy, DE | 1 |
| Mo, G | 1 |
| Shahir, A | 1 |
| Wright, J | 1 |
| DuBois, SG | 1 |
| Teepen, JC | 1 |
| van Leeuwen, FE | 1 |
| Tissing, WJ | 1 |
| van Dulmen-den Broeder, E | 1 |
| van den Heuvel-Eibrink, MM | 1 |
| van der Pal, HJ | 1 |
| Loonen, JJ | 1 |
| Bresters, D | 1 |
| Versluys, B | 1 |
| Neggers, SJCMM | 1 |
| Jaspers, MWM | 1 |
| Hauptmann, M | 1 |
| van der Heiden-van der Loo, M | 1 |
| Visser, O | 1 |
| Kremer, LCM | 1 |
| Ronckers, CM | 1 |
| Choi, MK | 1 |
| Kang, ES | 1 |
| Kim, DW | 1 |
| Ko, YH | 1 |
| Seok, H | 1 |
| Park, JH | 1 |
| Pyo, DH | 1 |
| Hoon Lim, D | 1 |
| Kim, SJ | 2 |
| Kim, WS | 1 |
| Cheah, CY | 1 |
| Herbert, KE | 1 |
| O'Rourke, K | 1 |
| Kennedy, GA | 1 |
| George, A | 1 |
| Fedele, PL | 1 |
| Gilbertson, M | 1 |
| Tan, SY | 1 |
| Ritchie, DS | 1 |
| Opat, SS | 1 |
| Prince, HM | 1 |
| Dickinson, M | 1 |
| Burbury, K | 1 |
| Wolf, M | 1 |
| Januszewicz, EH | 1 |
| Tam, CS | 1 |
| Westerman, DA | 1 |
| Carney, DA | 1 |
| Harrison, SJ | 1 |
| Seymour, JF | 1 |
| Landsburg, DJ | 1 |
| Petrich, AM | 1 |
| Abramson, JS | 1 |
| Sohani, AR | 1 |
| Press, O | 1 |
| Cassaday, R | 1 |
| Chavez, JC | 1 |
| Song, K | 1 |
| Zelenetz, AD | 1 |
| Gandhi, M | 1 |
| Shah, N | 1 |
| Fenske, TS | 1 |
| Jaso, J | 1 |
| Medeiros, LJ | 1 |
| Yang, DT | 1 |
| Nabhan, C | 1 |
| Schorb, E | 1 |
| Finke, J | 1 |
| Ferreri, AJ | 2 |
| Ihorst, G | 1 |
| Mikesch, K | 1 |
| Kasenda, B | 1 |
| Fritsch, K | 1 |
| Fricker, H | 1 |
| Burger, E | 1 |
| Grishina, O | 1 |
| Valk, E | 1 |
| Zucca, E | 1 |
| Illerhaus, G | 1 |
| Fischer, L | 3 |
| Korfel, A | 5 |
| Kiewe, P | 4 |
| Neumann, M | 2 |
| Jahnke, K | 2 |
| Thiel, E | 5 |
| Hong, SJ | 1 |
| Kim, JS | 1 |
| Chang, JH | 1 |
| Kim, KM | 1 |
| Lee, HW | 1 |
| Cheong, JW | 1 |
| Lee, ST | 1 |
| Min, YH | 1 |
| Conrad, AL | 1 |
| Go, RS | 1 |
| Pfeiffer, S | 1 |
| Volk, HD | 1 |
| Cakiroglu, H | 1 |
| Widmann, T | 1 |
| Wagner, T | 1 |
| Seyfert, S | 1 |
| Albrecht, H | 1 |
| Reinwald, M | 1 |
| Cabanillas, F | 1 |
| Martus, P | 1 |
| Kanz, L | 1 |
| Griesinger, F | 1 |
| Rauch, M | 1 |
| Röth, A | 1 |
| Hertenstein, B | 1 |
| von Toll, T | 1 |
| Hundsberger, T | 1 |
| Mergenthaler, HG | 1 |
| Leithäuser, M | 1 |
| Birnbaum, T | 3 |
| Herrlinger, U | 2 |
| Plasswilm, L | 1 |
| Nägele, T | 1 |
| Pietsch, T | 1 |
| Bamberg, M | 1 |
| Weller, M | 1 |
| Miwa, A | 1 |
| Sekiguchi, N | 1 |
| Tanimura, A | 1 |
| Homma, C | 1 |
| Shikai, T | 1 |
| Takezako, Y | 1 |
| Yamagata, N | 1 |
| Takezako, N | 1 |
| Patrij, K | 1 |
| Reiser, M | 1 |
| Wätzel, L | 1 |
| Pels, H | 2 |
| Kowoll, A | 1 |
| Engert, A | 2 |
| Linnebank, M | 1 |
| Schackert, G | 2 |
| Vogt-Schaden, M | 2 |
| Egerer, G | 2 |
| Lamprecht, M | 1 |
| Batchelor, TT | 1 |
| Schlegel, U | 2 |
| Schmidt-Wolf, IG | 2 |
| Motomura, K | 1 |
| Natsume, A | 1 |
| Fujii, M | 1 |
| Ito, M | 1 |
| Momota, H | 1 |
| Wakabayashi, T | 1 |
| Stadler, EA | 1 |
| von Baumgarten, L | 2 |
| Straube, A | 2 |
| Mappa, S | 1 |
| Marturano, E | 1 |
| Licata, G | 1 |
| Frezzato, M | 1 |
| Frungillo, N | 1 |
| Ilariucci, F | 1 |
| Stelitano, C | 1 |
| Ferrari, A | 2 |
| Sorarù, M | 1 |
| Vianello, F | 1 |
| Baldini, L | 1 |
| Proserpio, I | 1 |
| Foppoli, M | 1 |
| Assanelli, A | 1 |
| Reni, M | 1 |
| Caligaris-Cappio, F | 1 |
| Bochmann, K | 1 |
| Glasmacher, A | 1 |
| Schulz, H | 1 |
| Diehl, V | 1 |
| Zellner, A | 1 |
| Reichmann, H | 1 |
| Kroschinsky, F | 1 |
| Bode, U | 1 |
| Schaller, C | 1 |
| Deckert, M | 1 |
| Fimmers, R | 1 |
| Helmstaedter, C | 1 |
| Atasoy, A | 1 |
| Klockgether, T | 1 |
| López-Aguilar, E | 1 |
| Sepúlveda-Vildósola, AC | 1 |
| Rivera-Márquez, H | 1 |
| Cerecedo-Díaz, F | 1 |
| Valdés-Sánchez, M | 1 |
| Delgado-Huerta, S | 1 |
| Wanzke-del Angel, V | 1 |
| Ramón-García, G | 1 |
| Rodríguez-Jiménez, H | 1 |
| Hernández-Contreras, I | 1 |
| Santacruz-Castillo, E | 1 |
| Romo-Rubio, HA | 1 |
| Lokiec, F | 1 |
| Colombat, P | 1 |
| Lemevel, A | 1 |
| Bertrand, P | 1 |
| Delwail, V | 1 |
| Rachieru, P | 1 |
| Brion, A | 1 |
| Berthou, C | 1 |
| Bay, JO | 1 |
| Delepine, R | 1 |
| Desablens, B | 1 |
| Camilleri-Broët, S | 1 |
| Linassier, C | 1 |
| Lamy, T | 1 |
| Yamao, H | 1 |
| Kondo, E | 1 |
| Miura, A | 1 |
| Mizuno, H | 1 |
| Yuge, M | 1 |
| Spreafico, F | 1 |
| Massimino, M | 1 |
| Luksch, R | 1 |
| Casanova, M | 1 |
| Cefalo, GS | 1 |
| Collini, P | 1 |
| Polastri, D | 1 |
| Terenziani, M | 1 |
| Gasparini, M | 1 |
| Fossati-Bellani, F | 1 |
| Watts, RG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial[NCT02531841] | Phase 3 | 250 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | ||
| Phase IV Study on the Role of Whole Brain Irradiation in Primary CNS Lymphoma (PCNSL) After High-dose Methotrexate[NCT00153530] | Phase 4 | 604 participants (Anticipated) | Interventional | 2000-05-31 | Completed | ||
| A Phase II， Single-arm Trail of Chidamide Combined With Rituximab and High-dose Methotrexate in Previously Untreated Patients With Primary Central Nervous System Lymphoma[NCT04516655] | Phase 2 | 51 participants (Anticipated) | Interventional | 2020-09-01 | Not yet recruiting | ||
| Clinical Efficacy and Safety of IBER Salvage Treatment Followed by Ibrutinib Maintenance for Transplant-ineligible Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL): a Multicenter, Single-arm, Prospective Phase II Study[NCT04066920] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-10-01 | Not yet recruiting | ||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
2 reviews available for ifosfamide and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Contralateral testicular relapse after prophylactic radiation in a patient with primary testicular diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2009 |
Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Humans; Ifosfamide; Lymphoma; N | 2006 |
9 trials available for ifosfamide and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors.
Topics: Adolescent; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Central Nervous | 2021 |
High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neop | 2016 |
Penetration of ifosfamide and its active metabolite 4-OH-ifosfamide into cerebrospinal fluid of patients with CNS malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Central Nerv | 2011 |
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervo | 2010 |
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervo | 2010 |
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervo | 2010 |
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervo | 2010 |
Ranimustine, ifosfamide, procarbazine, dexamethasone, and etoposide therapy for central nervous system recurrence of diffuse large B-cell lymphoma in patients with poor performance status: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous Syst | 2011 |
Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclo | 2003 |
Preirradiation ifosfamide, carboplatin and etoposide (ICE) for the treatment of high-grade astrocytomas in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carboplatin; Central Nervou | 2003 |
High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; | 2006 |
High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; | 2006 |
High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; | 2006 |
High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neoplasms; | 2006 |
Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Central Nervous System | 2002 |
17 other studies available for ifosfamide and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Safety and efficacy of induction immunochemotherapy with rituximab, methotrexate, ifosfamide, and vincristine (R-MIV) in patients with primary CNS lymphoma including recent COVID-19 pandemic experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; COVID-19; Cytarabi | 2023 |
Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy.
Topics: Adolescent; Adult; Adult Survivors of Child Adverse Events; Aged; Antineoplastic Agents; Bone Neopla | 2017 |
Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central | 2013 |
A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma.
Topics: Acute Kidney Injury; Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Antibo | 2014 |
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Burkitt Lymphoma; Central Ner | 2016 |
Systemic high-dose methotrexate plus ifosfamide is highly effective for central nervous system (CNS) involvement of lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous Syst | 2009 |
A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Central Nervous System Neoplasms; Cy | 2009 |
CXCL13 and CXCL12 in central nervous system lymphoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2009 |
Topotecan and ifosfamide systemic chemotherapy for CNS involvement of solid tumors.
Topics: Aged; Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; Female; Humans; Ifosfamid | 2011 |
How important is whole brain radiotherapy for treatment of primary CNS lymphoma?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous Sys | 2010 |
Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclo | 2011 |
Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Central Nervous Sy | 2011 |
Rituximab significantly improves complete response rate in patients with primary CNS lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Central Nervous System N | 2012 |
Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Centra | 2013 |
Early relapses in patients with primary CNS lymphoma treated with methotrexate-based chemotherapy without consolidating whole brain irradiation.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nerv | 2013 |
[Successful treatment with high dose chemotherapy following peripheral blood stem cell transplantation for relapsed Burkitt's lymphoma with central nervous system involvement].
Topics: Adult; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; | 1998 |
Combination chemotherapy with ifosfamide and etoposide is effective in the treatment of central nervous system metastasis of childhood neuroblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Etoposide; Female; | 1992 |